Gufic Biosciences (BOM:509079) Tax Expense: ₹223 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:509079 Gufic Biosciences Ltd BOM:509079
77 GF Score
Price ₹387.95
GF Value ₹409.35
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Gufic Biosciences Tax Expense?

Gufic Biosciences BOM:509079 -2.07% 77 Tax Expense is ₹223 Mil as of Mar. 2026. GuruFocus rates BOM:509079 with a GF Score™ of 77/100 and a GF Value™ of ₹409.35 (Fairly Valued). The stock has 7 warning signs investors should review.

Gufic Biosciences's tax expense for the months ended in Mar. 2026 was ₹71 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹223 Mil.


Gufic Biosciences  (BOM:509079) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Gufic Biosciences Tax Expense Related Terms


Gufic Biosciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Tax Expense Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 309.98 270.16 295.36 244.95 223.36

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.05 42.04 57.82 52.97 70.55
BOM:509079
77GF Score
Gufic Biosciences Ltd BOM:509079
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹223 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of ₹223 Mil mean?
Gufic Biosciences (BOM:509079) has a Tax Expense of ₹223 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Gufic Biosciences and its competitors.
Is Gufic Biosciences' Tax Expense too high?
Gufic Biosciences' current Tax Expense is ₹223 Mil. Overall, Gufic Biosciences has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Tax Expense compare to ZTS and UTHR?
Gufic Biosciences' Tax Expense of ₹223 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Drug Manufacturers company?
A good Tax Expense depends on the Drug Manufacturers industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Gufic Biosciences and its competitors. Gufic Biosciences's current Tax Expense is ₹223 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹409.35, compared to a current price of ₹387.95 — trading 5.2% below its estimated fair value. The current Tax Expense is ₹223 Mil. Gufic Biosciences' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Tax Expense is ₹223 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹387.95 is trading 5.2% below its estimated GF Value™ of ₹409.35. GuruFocus considers Gufic Biosciences to be Fairly Valued.

Key valuation signals for BOM:509079:

  • Tax Expense: ₹223 Mil
  • GF Value™: ₹409.35 vs. price of ₹387.95 (5.2% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
77GF Score

Get the complete analysis for BOM:509079

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹387.95
Price
₹409.35
GF Value